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Abstract
An accurate and precisely annotated genome assembly is a fundamental requirement for functional genomic analysis. Here,
the complete DNA sequence and gene annotation of mouse Chromosome 11 was used to test the efficacy of large-scale
sequencing for mutation identification. We re-sequenced the 14,000 annotated exons and boundaries from over 900 genes
in 41 recessive mutant mouse lines that were isolated in an N-ethyl-N-nitrosourea (ENU) mutation screen targeted to mouse
Chromosome 11. Fifty-nine sequence variants were identified in 55 genes from 31 mutant lines. 39% of the lesions lie in
coding sequences and create primarily missense mutations. The other 61% lie in noncoding regions, many of them in highly
conserved sequences. A lesion in the perinatal lethal line l11Jus13 alters a consensus splice site of nucleoredoxin (Nxn),
inserting 10 amino acids into the resulting protein. We conclude that point mutations can be accurately and sensitively
recovered by large-scale sequencing, and that conserved noncoding regions should be included for disease mutation
identification. Only seven of the candidate genes we report have been previously targeted by mutation in mice or rats,
showing that despite ongoing efforts to functionally annotate genes in the mammalian genome, an enormous gap remains
between phenotype and function. Our data show that the classical positional mapping approach of disease mutation
identification can be extended to large target regions using high-throughput sequencing.
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Introduction
Genome sequences are essential tools for comparative and muta-
tional analyses [1,2]. As a part of the Mouse Genome Sequencing
Consortium, we sequenced mouse Chromosome 11 in the C57BL/6J
mouse strain. The 2002 draft mouse genome reported 8681 gaps in
mouse Chromosome 11, and was estimated to lack 4.3 Mb of
sequence, despite a good shotgun assembly and a physical map [3].
Using clone-by-clone sequencing of the physical map of mouse
Chromosome 11, we have assembled this chromosome into a near
contiguous sequence with the highest quality of any mouse
chromosome assembly (completed sequence is available in the NCBI
assembly of the mouse genome at www.ensembl.org).
The sequence of Chromosome 11 from C57BL/6J now pro-
vides a basis for understanding the trait characteristics of this
strain, for cross-strain comparative analysis, for identifying
modifiers and quantitative trait loci (QTLs), and for the precise
design of knockout alleles. Accurate DNA sequence also facilitates
the discovery of disease associated genes from forward genetic
screens, as well as the engineering of mutations and rearrange-
ments in the mouse to model human diseases.
We used the completed sequence to design primers to re-
sequence DNA from mutants isolated in a phenotype-driven
regional recessive N-ethyl-N-nitrosourea (ENU) genetic screen
targeted to mouse Chromosome 11 through the use of a balancer
chromosome [4,5]. ENU primarily induces point mutations, which
have been a challenge to fine map and identify [6]. Classical
positional cloning involves narrowing the molecular interval by
meiotic mapping, followed by candidate gene sequence analysis,
which is time consuming and expensive. Further, in many
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organisms, including Caenorhabditis elegans, Drosophila melanogaster,
and Escherichia coli, chemical point mutagens often generate a
multitude of linked lesions [7], which can confound the
designation of a candidate gene to the mutant phenotype. In the
mouse, genes are dispersed, chromatin contains large stretches of
noncoding sequence, and inbred strains with fixed genetic
backgrounds are readily available. We reasoned that mutations
isolated using the regional screen were ideal to test the efficacy of
mutation identification by sequencing after ENU point mutagen-
esis, because mutations were induced on a C57BL/6J chromo-
some, and because mutant recovery was targeted to an interval
between Trp53 and Wnt3, restricting the analysis to a 34 megabase
(Mb) region [5]. Mouse Chromosome 11 and its conserved
counterpart human Chromosome 17 are very gene dense, making
classical positional cloning efforts unrealistic for large numbers of
mutants. Identifying DNA lesions in mutant lines should assign
candidate genes, while it defines the numbers and nature of DNA
lesions detected after ENU treatment. We illustrate the value of
finished sequence by recovering a rich catalogue of candidate
genes in ENU-induced mutant lines. No mutations have been
reported previously for the majority of the candidate genes. Here,
we report for the first time that a splice-site mutation in
nucleoredoxin causes craniofacial defects in the perinatal lethal
line l11Jus13.
Results
The sequence of mouse Chromosome 11
The sequence of mouse Chromosome 11 (,4.6% of the mouse
genome) was generated by sequencing 910 bacterial artificial
chromosomes (BACs) from a linear physical array [8,9]. The
clone-by-clone sequencing of this chromosome generated over 4
million raw sequence reads, which were collapsed into 118.8 Mb
of finished sequence. The current assembly contains three main
contiguous sequences of approximately 31.4, 54.0 and 33.4 Mb
separated by two gaps, which were found by fiber-FISH to be 91
and 6kb, respectively (Table S1). An additional gap represents the
acrocentric heterochromatin. Thus, the physical length of the
chromosome is estimated to be 121.8 Mb. The telomeric half of
mouse Chromosome 11 (Mmu11) contains the equivalent of the
entire euchromatic region of human Chromosome 17 (Hsa17)
(Figure 1), with the exception of a small number of genes that
differ between the two organisms (Table S2).
Identifying ENU–induced lesions in the Mmu11/Hsa17
region
We previously described a screen for autosomal recessive mouse
mutants using the point mutagen ENU, which was targeted to the
Mmu11 regionmost highly conserved with Hsa17, a 34 Mb interval
between Trp53 andWnt3 (Figure 1) [5]. A large number of recessive
mutant lines with a wide range of phenotypes, including craniofacial
abnormalities, neurological defects, infertility, impaired growth, and
lethality, were isolated in the screen. Each of the mutants was
identified by its phenotype after breeding ENU-treated C57BL/6J
male mice, and was maintained in trans to a balancer chromosome,
which was derived from 129S5/SvEv embryonic stem (ES) cells. To
identify the DNA lesions responsible for the phenotypes in these
lines, we designed primers for the 14,000 annotated exons and
intron/exon boundaries from all of the protein coding genes in the
34 Mb interval (Table S3), representing approximately 17,000
sequence tags. We then carried out bi-directional sequencing of
PCR amplicons from DNA of either a homozygous or heterozygous
individual from each of 41 mutant lines, a total of over 14 Mb of
sequence covering 7.8 Mb of transcribed DNA from each line,
which represents approximately one-fourth of the total DNA
content of the 34 Mb balancer region. A total of 1727 sequence
variants were identified, but most occurred in multiple heterozygous
mutant lines and were previously published single nucleotide
polymorphisms (SNPs) between the C57BL/6J and 129S5/SvEv
strains [10].
Eighty-one unique potentially causative base pair changes were
identified in the mutant lines. Each lesion was confirmed by re-
sequencing of DNA PCR products amplified from 2–4 indepen-
dent phenotype-true animals and all appropriate controls (Figure
S1). However, five base changes in three mutant lines were
confirmed in only a subset of DNAs. This indicates that the ENU-
induced base change was present in the original DNA that was
sequenced, but did not segregate with the phenotype in other
animals and was therefore not causative of the phenotype (Table
S4). The remaining changes included five new SNPs, which may
be unique to our 129 substrain, or may not have been previously
reported. That these occurred in only one line each is possibly due
to the randomness of crossovers in each line. Twelve of the lesions
initially identified by sequencing were not confirmed in any
mutant animal whose DNA was re-sequenced.
The most common DNA base changes identified were AT-GC
transitions (42.2%). AT-TA transversions represented 29.7% of
the bases changes followed by GC-AT (10.9%), GC-TA (10.9%),
and AT-CG (6.3%). These data are similar to the most
predominant lesions reported for ENU-induced mutations after
treatment of mouse spermatogonia [11]. The numbers of
confirmed ENU-induced lesions per mutant mouse line fits a
Poisson distribution: no lesions were detected in eight mutant lines,
one lesion was confirmed in each of seventeen mutant lines, two
lesions in seven mutant lines, three lesions in five mutant lines, four
lesions in two mutant lines, and five lesions in two mutant lines
(X2(5df) = 3.99; p,0.001; see calculations in Materials and
Methods). This finding indicates that some mutant lines could
carry more than one nucleotide variant that either individually or
together produce a phenotype.
Of the 23 coding base changes identified in 19 different mutant
lines, only 4 were synonymous. The non-synonymous base pair
changes provide a valuable list of candidate genes for the ENU-
induced mutations. The genetic code assists in the interpretation of
these lesions, since such base changes cause obvious defects in
protein coding sequences. Three of the non-synonymous lesions
result in the insertion of a stop codon, which may cause protein
truncation or elicit nonsense-mediated decay. One of these
mutations, C4228T, which generates Q106X in l11Jus15, is in a
member of the mediator complex that directs transcription,
mediator complex 31 (Med31). Sixteen non-synonymous missense
mutations were identified, most of which occur as the sole lesion
within the DNA that was sequenced in a line (Table 1, Table S4).
Notably, we previously reported a missense mutation in the
postnatal lethal line l11Jus51, and this line was re-sequenced as a
positive control. The mutation E541V in Slc4a1 was the only
Author Summary
Here we show that tiny DNA lesions can be found in huge
amounts of DNA sequence data, similar to finding a needle
in a haystack. These lesions identify many new candidates
for disease genes associated with birth defects, infertility,
and growth. Further, our data suggest that we know very
little about what mammalian genes do. Sequencing
methods are becoming cheaper and faster. Therefore,
our strategy, shown here for the first time, will become
commonplace.
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confirmed lesion identified in 6.276106 bp sequenced from this
line, showing the sensitivity of detection, as well as demonstrating
the relatively low frequency of ENU lesions. Two mutant lines,
craniofacial08 (crf08) and the lethal line l11Jus52, contain two
missense mutations each. Crf08 has an isoleucine to valine
substitution (I207V) in olfactory receptor 394 (Olfr394) as well as
a lysine to glutamic acid substitution (K663E) in mediator complex
13 (Med13). L11Jus52 has a tyrosine to cysteine substitution
(Y340C) in the frizzled 2 homolog (Fzd2) and a glutamine to
proline substitution (Q341P) in the plexin domain containing 1
gene (Plxdc1).
To predict the likelihood that an amino acid change is
deleterious, we employed the SNAP (screening for non-acceptable
polymorphisms) algorithm using default parameters and full-length
protein coding sequences [12]. It predicts the neutrality of the
mutation, calculates the percent accuracy of this analysis, and
provides a reliability index (Table 1). The SNAP analysis revealed
that the I207V transition in Olfr394 is a neutral amino acid
change, while K663E in the transcriptional regulator Med13 is
non-neutral, suggesting that the mutation causes a functional
change. Both of the lesions in l11Jus52, Y340C in Fzd2 and
Q341P in Plxdc1, are predicted to cause a functional change.
Ultimately, confirmation of candidate genes will require transgenic
rescue or crosses with additional alleles.
Thirty-six of the 59 potentially causative base pair changes were
found in non-coding regions of genes, including 25 within introns,
2 in 59 untranslated (UTR) elements, 7 in 39 UTRs, and 2
downstream of a gene (Table 1). We did not sequence conserved
microRNAs in this project. However, a search of miRNA
information databases revealed that none of the ENU-induced
mutations lie within known miRNA sequences that may fall within
or near genes. Further, no consensus splice sites or start codons
were created by the lesions, though one consensus splice site was
destroyed. Therefore, the noncoding lesions present more of a
challenge to link cause and effect, since most of them occur within
introns or 39UTRs, and may affect gene regulation, splicing,
transcript stability, translational efficacy, or may have no effect
at all.
Because multi-species sequence conservation is often a predictor
of function, we compared a 100 base pair mouse sequence
surrounding each ENU-induced base change to that of six other
vertebrate organisms: human, rat, Rhesus monkey, horse, dog,
and chicken. The comparisons produce a number based on the
percent identity, which we have arbitrarily designated a ‘‘match
Figure 1. Synteny map of mouse Chromosome 11. Mouse Chromosome 11 is aligned with human chromosomes 22, 7, 2, 5, 1, and 17. Syntenic
regions are represented in the same color and lines indicate breaks of synteny. The mouse Chromosome 11 ENU mutagenesis screen was targeted to
the Trp53-Wnt3 (69 Mb–103.5 Mb) interval within the region most conserved with human Chromosome 17, indicated by the black lines.
doi:10.1371/journal.pgen.1000759.g001
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Table 1. Confirmed ENU–induced mutations that are potentially causative for the abnormal phenotype in each line.
Mutant Line Phenotype of Mutant Line Gene name Base Change* Lesion** Classification{
craniofacial (crf) 02 abnormal craniofacial morphology1 Hspb9 G653Ae G11R Non-Neutral 3/78%
crf08 abnormal craniofacial morphology1 Med13 A49310Ge K663E Non-Neutral 3/78%
Olfr394 A1219Ge I207V Neutral 2/69%
crf12 abnormal craniofacial morphology1 Centb1 T10645Ae V414E Non-Neutral 2/70%
Med13 C87859A3U noncoding
Gip A4968Ci noncoding
Mpdu15 T5105Ai noncoding
crf18 abnormal craniofacial morphology1 Klhl10 A4098Ge K55R Neutral 3/78%
crf26 abnormal craniofacial morphology1 Ccdc55 T33214Ae V516E Non-Neutral 2/70%
growth (gro) 01 decreased body size1 Dvl26 T8151Ge F453V Non-Neutral 2/78%
Traf4 T5526Ai noncoding
Nos2 A29970Gi noncoding
gro22 decreased body size Abr G51912Ti noncoding
decreased circulating cholesterol1 Abcc3 A29323Gi noncoding
Mbtd1 T51696Ci noncoding
Mett10d T13811Ai noncoding
gro41 decreased body size1 Stac2 C14382Ae R354R
gro42 decreased body size1 Nsf C106442Ai noncoding
infertile (inf)03 female infertility1 Sp6 T10900A3U noncoding
inf07 female infertility1 Plekhm17 T18282Ce S209P Neutral 1/60%
RP23-263M10.5 T33177Cd noncoding
RP23-350G1.1 G4223Ai noncoding
lethal Chr11(l11Jus)03 embryonic lethality (5.5–8.5 dpc3) Git1 A10267Ci noncoding
l11Jus05 embryonic lethality (9.5–12.5 dpc3) Med13 T87481A3U noncoding
l11Jus06 embryonic lethality (9.5–12.5 dpc3) RP23-185A18.9 C8461Ae C632stop
Tmigd1 T5212Ci noncoding
l11Jus08 embryonic lethality (9.5–12.5 dpc3) Zzef1 T95354Ai noncoding
l11Jus12 embryonic lethality (5.5–8.5 dpc3) Map3k148 A46941Te M908L Non-Neutral 2/70%
P140 T39151Ci noncoding
Tlk2 T92972Ce D568D
l11Jus13 perinatal lethality3 Nxn T136735Ai Splice site
Mlx T4599C3U noncoding
Mrpl27 C1086Ai noncoding
Nbr1 A17277Gi noncoding
RP23-396N4.2 T91284Ad noncoding
l11Jus14 embryonic lethality (9.5–12.5 dpc3) Stat34,9 G43695Ti noncoding
l11Jus15 embryonic lethality (13.5–18.5 dpc3) Med31 C4228Te Q106stop
Car10 A2624G5U noncoding
l11Jus22 perinatal lethality3 Scpep1 T20167Ce V237A Neutral 0/53%
Stat5a T22219Ci noncoding
l11Jus27 embryonic lethality (9.5–12.5 dpc3) Usp32 T107950Ci noncoding
Dhx58 T5507Ce S364S
l11Jus48 embryonic lethality (5.5–8.5 dpc3) Hes710 A1728Ge K22E Non-Neutral 3/78%
l11Jus49 embryonic lethality (5.5–8.5 dpc3) Acaca T165383Ci noncoding
l11Jus51 postnatal lethality with anemia1 Slc4a111 A9600Te E541V Non-Neutral 3/78%
l11Jus52 postnatal lethality3 Fzd2 A1955Ge Y340C Non-Neutral 4/82%
Plxdc1 A53039Ce Q341P Non-Neutral 3/78%
Aipl112 A630T5U noncoding
Atp6v0a1 T1610Ai noncoding
Socs7 T31367Ci noncoding
Candidate Disease Genes in ENU-Induced Mutants
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score’’. This analysis showed that the coding region mutations are
conserved, as expected. However, it also showed that many of the
noncoding mutations are located within highly conserved regions
as well (Figure 2). All of the non-coding regions were chosen for re-
sequencing because they lie near exons or are non-coding UTRs,
so one may expect them to be well-conserved, similar to the coding
regions. However, the coding region lesion match score averaged
493, whereas the noncoding lesion match score averaged 304. The
100 bases surrounding the T to A lesion in l11Jus13 within a
consensus splice site of nucleoredoxin (Nxn) produced a match
score of 481. Both l11Jus05 and crf12 have independent mutations,
T to A and C to A, respectively, in the 39UTR of Med13 (the same
gene with a coding mutation in crf08), which occur in regions that
produced match scores of 568 and 561, respectively (Figure 2 and
Table S5). The regions surrounding these two noncoding lesions
had the highest match scores in our conservation analysis. Either
of these mutations may cause a change in message stability or
translation, perhaps through perturbations of interactions with
microRNA. Indeed, an analysis of TargetScan revealed that the
lesion in l11Jus05 lies within a seed sequence for the microRNA
miR200 [13,14].
A consensus splice site mutation in nucleoredoxin in the
perinatal lethal line l11Jus13
We examined the lesions in l11Jus13, a line that carried five
confirmed noncoding mutations in the novel Riken Protein RP23-
396N4.2, 39S ribosomal protein L27 (Mrpl27), next to Brca1 gene
(Nbr1), max-like protein X (Mlx), and nucleoredoxin (Nxn). These
lesions give match scores in our conservation analysis of 180, 202,
260, 410, and 481, respectively. The critical interval for the
l11Jus13 perinatal lethal phenotype was narrowed by meiotic
mapping to 6 Mb of DNA extending from the SNP rs3702197 to
the SNP rs13481117 (Figure 3A). All lesions other than that in Nxn
are excluded from this region. The T to A lesion in Nxn occurs two
base pairs after exon 6 to alter a consensus splice donor sequence.
RT-PCR and sequencing confirmed that the mutation leads to
aberrant splicing of the transcript in homozygous l11Jus13
(NxnJ13/J13) embryos. Thirty base pairs of intronic sequence are
included in the transcript, predicting an in-frame insertion of 10
amino acids into the protein, which was present in E12.5
homozygous mutants at about 30% of wild-type levels
(Figure 3B–3F) [15]. A null allele of Nxn was obtained from the
European Conditional Mouse Mutagenesis Program (EUCOMM),
Nxntm1Eucomm/+ (Nxn+/2), and a complementation test was carried
out. Thirty-four mice from crosses between Nxn+/2 and NxnJ13/+
were examined at weaning and none (Expected= 8) were NxnJ13/2
(p,0.001).
Ninety-seven percent of the NxnJ13/J13 mutants die perinatally
by postnatal day 1 (P1) (Figure S2) [16]. All NxnJ13/J13 embryos
had craniofacial dysmorphology (Figure 4A and 4B), and most had
cleft palates. Skeletal preparations at E18.5 showed that NxnJ13/J13
embryos had a seven percent decrease in mandible length
(p,0.001) when compared to their control littermates (Figure 4A
and 4B). The decrease in bone length was not found in femurs and
Mutant Line Phenotype of Mutant Line Gene name Base Change* Lesion** Classification{
l11Jus54 postnatal lethality3 Fzd2 G2447Ae C504Y Non-Neutral 4/82%
l11Jus55 postnatal lethality3 Nf113 A5492G3U noncoding
l11Jus58 embryonic lethality (after 12.5dpc3) Cntnap1 C17008Ti noncoding
Mrps23 G1465Ae K36K
neurological (nur) 07 decreased body size, Aspa14 C13844Te Q193stop
late onset tremors1 RP23-467J12.1 A14611G3U noncoding
RP23-352L3.2 T7179Ae D916E Neutral 4/85%
nur08 hyperactive, seizures, craniofacial1 RP23-185A18.9 T4392Ai noncoding
nur09 hyperactive, jerky, hearing loss1 RP23-136D4.2 T134653A3U noncoding
The average amount of sequence obtained for each mutant was 80% of the 7.8Mb (one-fourth) of the 34 Mb region containing exons of annotated genes. The mouse
gene symbol is shown. Location of lesion indicated by e (exon), i (intron), 5U (59 UTR), 3U (39 UTR), u (upstream), or d (downstream). No lesions were found in the mutant
lines crf05, inf4, gro40, l11Jus38, l11Jus45, nur01, nur05, and skc1. Lesions were identified in the mutant lines crf06 and l11Jus39 that confirmed in some, but not all of the
samples, indicating that the lesion was not causative of the phenotype, so these mutants are not included in the table.
*Number refers to nucleotide position within entire genomic sequence from Ensembl v52.
**Number refers to amino acid position within the first protein coding transcript in Ensembl v52.
{SNAP analysis was used to determine the likelihood of an amino acid change being deleterious to the protein. The resulting classification is shown as Neutral or non-
Neutral, along with the reliability index on a scale from 0 to 9, with 9 being the most reliable prediction, and finally, the predicted accuracy, shown as a percentage. This
analysis is based on human sequence, so may not be as reliable for the mouse.
1Kile et al. [5].
2Clark et al. [56].
3Hentges et al. [16].
4Stat3 is not the causative lesion because l11Jus14 maps to the Mpo-Chad interval and Stat3 is outside this interval.
5Associated with mutation in human gene MPDU1, OMIM 6040410.
6Associated with mouse mutant MGI 106613.
7Associated with mutation in human gene PLEKHM1, OMIM 611466, and a rat mutation, MGI 2443207.
8Associated with mouse mutant MGI 1858204.
9Associated with mutations in human gene STAT3, OMIM 147060, and mouse mutant MGI 103038.
10Associated with mouse mutation MGI 2135679.
11Associated with mutations in human gene SLC4A1, OMIM109240, and mouse mutant, MGI 109393.
12Associated with mutation in human gene AIPL1 OMIM 604393.
13Associated with mutation of human gene NF1, OMIM 601321, OMIM 607785, and mouse mutant MGI 97306.
14Associated with mutation in human gene ASPA, OMIM 271900.
doi:10.1371/journal.pgen.1000759.t001
Table 1. Cont.
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body mass was not significantly different at this time point,
showing that this decrease was not due to a body size difference in
the mutants (Figure S2).
Discussion
Mouse Chromosome 11 is the first full mouse chromosome to
be completely finished. Here, we analyzed the most conserved
region between mouse Chromosome 11 and human Chromosome
17 by mutagenesis and sequencing in the largest ENU mutation
identification project to date. This chromosome contains 4.6% of
the total mouse genome sequence, yet contains nearly 10% of the
estimated total number of transcribed genes, showing that mouse
Chromosome 11 is a gene dense region. Previous data suggested
that this region contains more than the average number of
essential genes [17], consistent with a high recovery of mutations
in the Chromosome 11 screen [5]. Classical positional cloning
efforts would have required many crosses in each mutant line to
narrow the critical intervals to a region small enough to re-
sequence, which would have been a massive effort for 41 mutant
lines.
Fifty-nine unique lesions were confirmed in 55 genes in 31 of
the mutant lines. The simplest of these to associate with candidate
genes are those that alter the coding sequence of a gene, although
any of the lesions reported here could be predicted to be causal
until proven otherwise. An F453V mutation in Dvl2, an activator
of Wnt signalling, occurred in the growth mutant gro01. The
knockout of Dvl2 dies perinatally of heart defects [18], so gro01
may be a hypomorphic allele of Dvl2. Two independent mutations
in the Wnt receptor Fzd2 occurred in the mutant lines l11Jus52
(Y340C) and l11Jus54 (C504Y). Fzd2 has not been targeted by
mutation previously. The aspartoacylase (Aspa) mutation in
nur07 (Q193X) represents a model of human Canavan disease, a
progressive disorder of myelination [19]. By far, the majority of
ENU-induced base changes that were identified occur in genes
that have no known function or for which no mutations have been
reported, including many full-length RIKEN cDNA sequences, a
plekstrin homology domain protein (Plekhm1), and the mediator
complex components Med13 and Med31. The causative nature of
four (K22E in Hes7, E541V in Slc4a1, Q193X in Aspa, and Q105X
in Med31) of the candidate gene mutations has been shown by
complementation tests or protein studies prior to this publication
[5,19] (and data not shown), and one in Nxn reported here;
however, the causal nature of others remains to be demonstrated.
A large proportion of the lesions occurred in noncoding regions.
Multi-species conservation analysis was carried out to predict
whether these lesions lie in a significantly conserved region
(Figure 4). In the lethal line l11Jus13, which carries 5 independent
noncoding mutations, a splice-site lesion in Nxn, which lies in a
highly conserved region, is responsible for the mutant phenotypes.
Of note, the five lesions in this line were well-spaced (at 76 Mb,
94.5 Mb, 101 Mb, 101.5 Mb, and 104.5 Mb), and none other
than that in Nxn was found in a 6 Mb critical interval that contains
over 180 genes. Although the l11Jus13 line had five base changes,
it was the exception. Seventeen of the lines had only one base
change in the entire 7.8 Mb of DNA that was sequenced.
Together, our data suggest that in the majority of ENU-induced
mouse mutant lines, accessory DNA lesions will not complicate
assigning mutations to phenotypes.
NxnJ13 homozygous mutants likely die as a consequence of cleft
palate, which causes an inability to suckle at birth (Figure S2).
Cleft lip and/or cleft palate is a common birth defect, which can
Figure 2. Conservation analysis of sequence surrounding ENU–induced lesions. A graph of match scores shows that exons and some non-
coding elements are highly conserved. The match score is based on a 100 base pair comparison across seven vertebrates: mouse, human, rat, Rhesus
monkey, horse, dog, and chicken. Red = lesion occurred in an exon, blue= lesion occurred in a 59 or 39 UTR, green= lesion occurred in an intron, and
yellow= lesion occurred downstream of a gene.
doi:10.1371/journal.pgen.1000759.g002
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be caused by the tongue protruding into the space where the
palate should close during embryogenesis [20,21]. Therefore, the
cleft palate in NxnJ13 homozygous mutants could be due to a
physical failure of the palate to fuse as a consequence of the small
mandibles causing a protrusion of the tongue. Nxn lies within the
region commonly deleted in Miller-Dieker Lissencephaly Syn-
drome (MDLS—OMIM #247200). Patients with this disorder
sometimes have micrognathia (small jaw), cleft palate, and heart
defects, raising the possibility that Nxn plays a role in the
pathogenesis of this disease [22]. In addition, the triad of
glossoptosis (displacement of the tongue), micrognathia, and cleft
palate is seen in Pierre Robin syndrome (OMIM #261800).
Recently, an autosomal dominant form of this disorder was
associated with deletions around the SOX9 gene on 17q (OMIM
#608160); however, there are clearly still autosomal recessive
forms of this disease for which the underlying genetic lesion has yet
to be identified [23], and NXN is a promising candidate gene for
these cases. Nxn has been previously implicated as a negative
regulator of the canonical Wnt pathway and the noncanonical
PCP pathway in cell culture and in Xenopus [24,25]. Disrupting the
signalling of either or both of these pathways could result in the
craniofacial abnormalities observed in the NxnJ13/J13 mutants.
In spite of the large number of candidate genes reported here,
we know that our mutation detection is incomplete. Our overall
mutation rate was 2.661027, which is within the published range
for mutation rates defined after ENU treatment and sequencing
(1.0461026 to 3.161027) [26,27]. We predict that we have
identified 36–100% of the possible lesions in our mutants. Prior
searches for point mutations in an allelic series at myosin light
chain 5a (Myo5a; dilute) and bone morphogenetic protein 5 (Bmp5;
Figure 3. Mutation of nucleoredoxin in l11Jus13 (NxnJ13/J13). (A) Haplotype map of 239 unaffected and 83 affected mice used for meiotic
mapping. The location of each marker and Nxn is displayed (Ensembl v52). The mutation lies in a 6Mb region located between rs3702197 and
rs13481117. (B) The Nxn locus is depicted with introns 6 and 7 boxed. (C) The boxed region is expanded to illustrate the consequence of splicing in
the wild type and mutant. A transversion (T to A) abolishes a consensus splice donor site leading to aberrant RNA splicing. The six base pair cryptic
splice site used in the mutant is underlined. (D) Aberrant splicing in NxnJ13/J13 predicts an in frame insertion of 10 amino acids, GMELEGKWKA, (white),
which occurs within the acidic region (black) of Nxn. (E) RT–PCR using primers flanking exon 6–7 from pools of three E14.5 heads of wild-type,
heterozygous, and homozygous mutants demonstrates aberrant splicing in the mutant allele. (F) Western blots of Nxn and Actin from wild-type,
heterozygous and homozygous mutants at E12.5 show reduced protein in the homozygous mutant. A reduction in protein was also observed at
E15.5 and E18.5, and a polyclonal antibody against the N-terminus gave similar results (data not shown).
doi:10.1371/journal.pgen.1000759.g003
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short ears), failed to identify approximately 1/3 of the lesions
within annotated coding sequences [28–30]. Further, two of five
ENU-induced alleles of quaking (qk) lie outside the coding region
or the 59 and 39 UTRs [31,32]. Despite extensive efforts to
catalogue the coding component of mouse Chromosome 11, it is
likely that there are genes, particularly those expressed at discrete
developmental time points or in rare cell types that have not been
annotated. However, some of the missing Bmp5 lesions were later
shown to lie in regulatory regions [33]. Here, we show that many
of the ENU-induced lesions lie in non-coding regions, even though
our exon-based sequencing strategy targeted only 125 base pairs
outside each exon along with the 59 and 39 UTRs. We would
predict that the mutants reported here have additional lesions in
non-coding regions that were not sequenced in this project or in
the exon sequences that were not obtained for each mutant. Some
of these may lie in regulatory regions.
The first ENU-induced mutation discovered to disrupt the
sequence of a microRNA was recently reported to cause deafness
[34]. MicroRNAs were not previously included in re-sequencing
strategies for candidate genes, because they were not annotated. We
report the first lesion in a miR200 seed sequence in the 39 UTR of
Med13 in the lethal line l11Jus05, which dies at E 8.5 with
cardiovascular and neural tube defects [16]. Med13 is a component
of the mediator complex, which associates with RNA Polymerase II
to direct transcription. It is expressed during embryonic develop-
ment and throughout the brain and skeleton in the adult [35]. The
mediator complex is required during development as evidenced by
the fact that deletion of the components Med1 and Med21 produce
embryonic lethal phenotypes due to cardiac defects [36,37].
MiR200 is required for the mesenchymal/epithelial transition
during embryonic development and is involved in cancer metastasis
[38,39]. Further studies of this mutation will help us to determine
how miR200 regulates Med13. Future sequencing efforts in any
project designed to identify causes of mutation or disease should
include microRNAs, 39 and 59UTRs, and any other highly-
conserved noncoding regions. Although the functional nature of
many conserved noncoding regions is not apparent, perhaps some
of our mutations will allow us to determine the ‘‘genomic code’’ in
non-coding conserved sequences.
As polymorphisms are detected in Genome Wide Association
Studies (GWAS), the correlation of SNPs or copy number varia-
tion with disease will require knowledge of the biological function
of each gene. Of the over 900 annotated transcripts in the
Trp53-Wnt3 interval, 27% are associated with mutant pheno-
types from gene targeting or spontaneous mutation (Table S6).
However, only six of the candidate genes reported here have been
targeted by mutation in the mouse (Mapk14 [40,41], Hes7 [42],
Slc4a1 [43], Stat3 [44], Nf1 [45], and Dvl2 [18]), and only one in the
rat (Plekhm1) [46]. Seven genes are associated with disease
mutations in the Online Mendelian Inheritance in Man database
(OMIM) (MPDU1 [47], PLEKHM1 [46], STAT3 [48], SLC4A1
[49], NF1 [50], AIPL1 [51] and ASPA [52]), of which five are
associated with mutations in mouse or rat (Table 1). Therefore,
prior to this study, function was associated with only nine of the
genes we report, showing that the majority of the lesions reveal
new functions for the candidate genes. In aggregate, these data
show that functional annotation of the mouse genome is still in its
infancy, especially when one considers the low degree of saturation
of our mutagenesis screen [17]. The mouse genome has a
tremendous potential to provide biological and experimental
annotation of both genes and noncoding conserved sequences
relevant to GWAS, if this gap between function and phenotype is
to be bridged.
Here we show that re-sequencing must no longer be restricted
to a few candidate genes. Faster, cheaper, high-throughput
methods for re-sequencing reduce the need for narrowing
Figure 4. NxnJ13/J13 mutants have cleft palates and small mandibles. Homozygous NxnJ13/J13 embryos were compared to NxnJ13+/+Inv control
littermates. (A) Gross morphology at E18.5. NxnJ13/J13 mutants (right) have a shortened snout compared to control littermates (left). (B) The palate
(inside the dotted lines) was examined at E18.5, and a cleft palate (yellow arrow) occurred in NxnJ13/J13 embryos (right) but not in control littermates
(left). (C) Skeletal preparations were carried out at E18.5. The mandible is shorter in length in NxnJ13/J13 embryos (bottom) than in control littermates
(top). (D) The mean and standard error are plotted to show the difference in mandible length. Mutant mandibles are significantly (p,0.001) shorter
than controls (n = 10 mandibles per genotype).
doi:10.1371/journal.pgen.1000759.g004
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candidate gene intervals to small regions by meiotic mapping.
Targeted re-sequencing using Next Generation (NextGen) tech-
nologies should be attempted for mutation detection in additional
mutant lines that map to restricted molecular intervals. The
classical microcapillary sequencing method has a relatively low
error rate. However, comparisons of the efficacy of the various
NextGen methods show that each is sequence context dependent
[53,54]. Regardless of error rate, cost or ease of use, our data show
that although most sequencing methods are exon-based, strategies
used for mutation detection should include conserved non-coding
as well as coding sequences, also known as the ‘‘conservome’’ [54].
Altogether, accurate genome sequence and cheaper sequencing
technologies provide a new avenue for understanding genomes,
genome evolution, disease mutations and biological function.
Materials and Methods
Ethics statement
All animal work was approved by the Institutional Animal Care
and Use Committee (IACUC). Our animal facility is accredited by
the Association for Assessment and Accreditation of Laboratory
Animal Care International (AAALAC).
Mapping, sequencing, and sequence analysis
The sequence of mouse Chromosome 11 was generated using a
hierarchical strategy to generate a sequence-ready physical map of
the chromosome followed by clone-by-clone sequencing to
generate high-quality finished sequence.
Alignments for cross species comparative analysis were
performed with WU-BLASTN (http://blast.wustl.edu) using the
finished sequence assembly of mouse Chromosome 11 (National
Center for Biotechnology Information (NCBI) build 37) and of the
human genome (NCBI 37). All sequences were repeat-masked
with RepeatMasker (http://repeatmasker.genome.washington.
edu) and low-quality alignments (E-value .10230) were removed
prior to analysis.
We performed manual annotation of the finished mouse
Chromosome 11 following the human and vertebrate analysis
and annotation (HAVANA) guidelines (http://www.sanger.ac.uk/
HGP/havana/) to identify 2,545 gene structures (approximately
30% higher than previous computational predictions alone), which
include 1,597 protein-coding loci, 450 processed transcripts, and
498 pseudogenes (Table S2). Before the process of manual
annotation, an automated analysis pipeline for similarity searches
and ab initio gene predictions was run, and the resulting data were
manually annotated using the graphical in-house annotation tool
‘‘otterlace’’. Manual gene annotation is available in Vega (http://
vega.sanger.ac.uk/index.html) [55]. Protein coding loci were
subcategorized into known and novel loci depending on whether
the cDNA had an entry in RefSeq (human loci) or Mouse Genome
Database (mouse loci). If no open reading frame could be
determined the locus was classified as a transcript and labeled
novel or putative, depending on level of supporting evidence.
ENU mutagenesis balancer screen and exon sequencing
The Chromosome 11 ENU mutagenesis screen was performed
as described previously using C57BL/6J ENU-treated males and
the 129.Inv(11)8BrdTrp53-Wnt3 balancer chromosome [4,5]. The
inversion was generated in 129S5SvEv ES cells, and restricts the
recovery of viable recombination products, so the region should
remain 129S5 in subsequent crosses. After isolating a line based on
its phenotype, animals were mated at least four times (N4) to a
129S6/SvEv or congenic 129S6.Rex line to allow for recombina-
tion, and then each line was maintained in trans to 129.Inv11(8)Brd.
Sequences for the exons and their 1kb flanking sequences were
extracted from Vega for all known protein-coding genes, novel
coding sequences, and transcripts in the target region. Repeats in
the sequence were masked using RepeatMasker (http://www.
repeatmasker.org/) prior to primer design. Primers were designed
automatically using Primer3 (http://frodo.wi.mit.edu/) to amplify
each exon and at least 125bp on either side of the exon with an
optimum amplicon size of 450–550bp. A series of overlapping
primer pairs was designed for each larger exon to obtain complete
coverage. Any exons failing automatic primer design had primers
designed manually. Primer pairs were checked for uniqueness
prior to ordering and pre-screened to determine the optimum
conditions for amplification.
Amplification was routinely performed on 48 DNA samples
with 8 sequence tagged sites (STSs) for each sequence run. For
initial large-scale sequencing, only one DNA from each mutant
line was used. Because 7.8 Mb of transcribed linear DNA was
sequenced per line for both strands, a total of over 560 Mb of
DNA sequence was analyzed. One line reported here, l11Jus48,
was not sequenced for the entire region because the causative
lesion was found by concurrent candidate gene sequencing. The
majority of exons were amplified at 60uC. After amplification, an
aliquot of the product was visualized on an agarose gel. Prior to
sequencing, the remaining PCR product was purified using
Exonuclease 1 and Shrimp Alkaline Phosphatase. Bi-directional
sequencing of amplicons was carried out using Big Dye chemistry.
For more details, please refer to http://www.sanger.ac.uk/
humgen/exoseq/. SNPs were called using ExoTrace (http://
www.sanger.ac.uk/humgen/exoseq/analysis.shtml), a novel algo-
rithm developed in-house for the detection of sequence variants.
The program works by comparing actual peak heights with the
expected peak height for a homozygous base. A base is called as
homozygous if the relative peak height in a single channel exceeds
a threshold and the signal in all other channels is significantly
smaller than the expected peak height. A base is called as
heterozygous if the signal in two channels is approximately half the
expected homozygous peak height and there is no significant signal
in the other channels. ExoTrace processes the sense and antisense
sequence reads separately and subsequently combines the results
to allow SNP scoring. Each SNP is assigned a status according to a
set of pre-defined rules. All SNPs below a certain threshold were
subjected to manual review using a modified version of GAP4,
part of the Staden Sequence Analysis Package software (http://
staden.sourceforge.net/), created for the ExoSeq project.
Re-sequencing for confirmation of mutations
Eighty-one of 1727 sequence variants that were identified in first
pass sequencing were chosen for re-sequencing. Comparisons of
sequence from each mutant line against every other line provided
a control for SNPs in the B6 and 129 substrains. ENU-induced
lesions that are causative are expected to occur only once in a
single mutant line. Primers were designed manually using Primer3
(v.0.4.0, http://frodo.wi.mit.edu) to flank the candidate mutations
(Table S7). Genomic DNA was phenol-chloroform extracted from
livers, embryos, or tails from homozygous or heterozygous mutants
was PCR-amplified and sequenced directly using the PCR primers
and BigDye Terminator v3.1 (Applied Biosystems) according to
the manufacturer’s instructions. The sequencing chromatograms
were analyzed with Sequencher 4.7. The locations of the
mutations are displayed on Ensembl v52.
Mouse strains and genotyping
The l11Jus13 (NxnJ13) mutation is maintained in trans to
129.Inv(11)8BrdTrp53-Wnt3 [4]. The NxnJ13+/+Inv line was crossed
Candidate Disease Genes in ENU-Induced Mutants
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five times to congenic 129S6.Rex+/+Inv mice, to recover Rex+/
+NxnJ13 animals and allow for recombination. Mice were
genotyped with D11Mit327 or D11Mit132 for embryonic and
neonatal studies prior to the identification of the causative lesion.
The line was crossed four additional times to the 129S6/SvEvTac
inbred mouse strain after the mutation was found, creating a new
congenic line 129S6.NxnJ13. DNA was prepared from mouse tails,
embryonic tissue, or yolk sac by either phenol/chloroform
extraction or alkaline lysis (tissue is treated with 50 mM NaOH
at 95uC for 20 minutes, followed by neutralization with 1/5
volume of 0.5 M Tris, pH 8.0). Genotyping of embryos, neonates,
and adult mice was performed by PCR analysis of at least two STS
markers flanking nucleoredoxin. Primer pairs for three different
STS markers were used: 1) D11Bhm148 (Forward primer 59-
AGGGGAAGTCCTGTATGGACA-39 and Reverse primer 59-
ACCAACCTCGATAGAGCCATC-39), 2) rs13481111 (F-GTA-
AGGACAAAGAGGACTGCCAAG and R-AATGACAGAC-
AGGAGGAAATCCAT), or 3) D11Mit245 (F-ATGAGACCAT-
GCTCCTCCAC and R-TTGTCCTCTGACCTTCACACC).
The PCR mixture contained 56 Promega GoTaq PCR buffer,
0.3 mM dNTPs, 0.5 mM primer mix, 250 ng template, and
0.25 U Taq Polymerase (New England Biolabs). Cycling condi-
tions for D11Bhm148 were: 94uC 5 min; 40 cycles of 94uC 45 sec,
55uC 45 sec, 72uC 45 sec; then 7 min at 72uC; followed by
incubation at 4uC. The PCR products (C57BL/6J - 97 bp,
129SvEvTac - 107 bp) were resolved on 4% NuSieve gels (Lonza).
Cycling conditions for rs13481111 were: 94uC 5 min; 40 cycles of
94uC 45 sec, 57uC 45 sec, 72uC 45 sec; then 7 min at 72uC;
followed by incubation at 4uC. Digestion of the 236 bp PCR
product with Sau96I (New England Biolabs) yields 2 bands for
C57BL/6J (72 and 164 bp) and one for 129SvEvTac (236bp band
remains uncut). These products were resolved on 2.5% SeaKem
LE agarose gels (Lonza). The cycling conditions for D11Mit245
were: 94uC 5 min; 40 cycles of 94uC 45 sec, 60uC 45 sec, 72uC
45 sec; then 7 min at 72uC; followed by incubation at 4uC. The
PCR products (C57BL/6J - 152 bp, 129SvEv - 140 bp) were
resolved on 5% MetaPhor gels (Lonza).
To generate the Nxntm1EUCOMM (Nxn2/2) allele, C57BL/6N JM8
ES cells containing a multipurpose conditional ‘‘knockout-first’’
construct targeted to Nxn were obtained from the European
Conditional Mouse Mutagenesis Program (EUCOMM). These
ES cells were injected into C57BL/6Brd Tyr2/2 blastocysts and
implanted into pseudopregnant mothers. Male chimeric offspring
with black and white coats were then mated to C57BL/6Brd Tyr2/2
females, and black progeny were genotyped for the knockout-first
allele with the following primers: NxnFor (TTGGGTATGCCC-
GACTCCCCCACC), NxnRev (CCTTCAGCCCTCTCCTT-
TCTGTGC), and loxPrev (TGAACTGATGGCGAGCTCAGA-
CC). Two PCR reactions were set up for each sample, one with
NxnFor and NxnRev, which gives a 435 bp PCR product from the
mutant and a 568 bp product from wild-type, and one with NxnFor
and loxPrev, which gives a 228 bp PCR product from the mutant,
but none from the wild-type. PCR conditions were: 56 Promega
GoTaq PCR buffer, 0.3 mM dNTPs, 0.5 mM primer mix, 250 ng
template, 1M betaine, 0.25 U Taq Polymerase (New England
Biolabs). The cycling conditions were as follows: 94uC 5 min; 40
cycles of 94uC 45 sec, 56uC 45 sec, 72uC 45 sec; then 7 min at
72uC; followed by incubation at 4uC. The PCR products were
resolved on 2% agarose gels.
Meiotic mapping
Meiotic mapping was performed by crossing NxnJ13+/+Inv to
congenic 129S6.Rex/Rexmice, followed by intercrossing NxnJ13+/+Rex
mice, and examining the progeny for recombination events. Embryos
and neonates with an abnormal facial structure and a cleft palate
were classified as affected progeny (n= 82), and mice that survived
to weaning were classified as unaffected progeny (n= 239). Two or
more polymorphic markers between the C57BL/6J and 129S6/
SvEvTac strains were analyzed for every DNA sample, which
was obtained from embryonic tissue or adult mouse tails by
phenol/chloroform extraction. The following microsatellite mark-
ers were assessed: D11Mit4, D11Mit219, D11Mit322, D11Bhm148,
D11Mit245, D11Mit120, D11Mit324, D11Mit39, D11Mit327,
D11Mit132, and D11Mit333. The following SNPs were assessed:
rs3702197, rs13481111, rs13481113, rs13481117, and rs13481125.
Primer sequences and restriction enzymes used to digest the SNPs
are shown in Table S8.
RT–PCR and sequencing
RNA was made from pools of three E14.5 heads and livers with
RNA STAT-60 (Tel-Test), and treated with DNase I (Invitrogen)
following the manufacturer’s instructions. Twomicrograms of RNA
were reverse transcribed into cDNA using SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen) with random
hexamers following the manufacturer’s instructions. Gapdh was used
as a positive control using the following primers: F-CGGAGT-
CAACGGATTTGGTCGTAT and R-GCCTTCATGGTGGT-
GAAGAC. Cycling conditions were: 94uC 5 min; 30 cycles of 94uC
30 sec, 60uC 30 sec, 72uC 30 sec; then 7 min at 72uC; followed by
incubation at 4uC. NxnRT-PCRwas carried out using the following
primers: F-GGTGCTCAATGACGAGGACT and R-GCCTC-
CTCTTCTTTGGCTTT, which amplified the junction between
exons 6–7 (213 bp wild-type product and 243 bp mutant product).
Cycling conditions were: 94uC 5 min; 35 cycles of 94uC 45 sec,
60uC 45 sec, 72uC 45 sec; then 7 min at 72uC; followed by
incubation at 4uC. The PCR products were gel extracted, cleaned
with Zymoclean Gel DNA Recovery Kit (Zymo Research), and
sequenced directly using the PCR primers and Big Dye Terminator
v3.1 (Applied Biosystems). The Big Dye terminator was removed
with Centri.Sep 8 (Princeton Separations), according to the manu-
facturer’s instructions. Sequencing was performed by the Child
Health Research Center (Baylor College of Medicine) and the
sequencing chromatograms were analyzed with Sequencher 4.7.
miRNA analysis
The miRBase Sequence Database (http://www.mirbase.org/)
was used to identify 18 known miRNA sequences that lie within
the Chromosome 11 balancer region. Two miRNAs, mmu-mir-324
and mmu-mir-423, lie within genes in which mutations were found,
dishevelled 2 (Dvl2) and coiled-coil domain containing 55 (Ccdc55),
respectively, though neither mutation identified in these genes is
within the miRNA sequence itself. Target Scan 4.2 (http://www.
targetscan.org/) was used to determine if any of the mutations that
did not cause amino acid changes had altered a known conserved
miRNA target.
Western blot analysis
Total embryo protein extracts were prepared by grinding embryos
in reducing 26 SDS sample buffer (200 mM Tris-HCl pH 6.8,
3% w/v SDS, 20% v/v glycerol, 10% v/v b–mercaptoethanol,
4% v/v saturated bromophenol blue solution) using a Tekmar
electronic tissue homogenizer. Samples were resolved by SDS-
PAGE on a precast 4–20% Tris-HCl polyacrylamide gel (Bio-Rad)
and transferred to a Hybond ECL nitrocellulose membrane
(Amersham). Nucleoredoxin was visualized using the previously
described polyclonal anti-Nxn antibody [24], which was made
against full-length protein and purified against a C-terminal
fragment. Experiments were repeated using a polyclonal antibody
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made against an N-terminal fragment of Nxn as well [24].
Primary antibody (1:1000 of 0.5 mg/mL stock) incubation was
followed by an anti-rabbit secondary antibody (1:10,000 of
0.8 mg/mL stock) linked to horseradish peroxidase (Jackson
Immunoresearch) and detected on Hyperfilm ECL film using the
ECL Plus Western Blotting Detection kit (Amersham) according
to the manufacturer’s instructions. Actin was used as a loading
control and was visualized similarly using the rabbit anti-actin
antibody (A2066) from Sigma.
Embryo and neonate examination
Timed matings were carried out on intercrosses between
NxnJ13+/+Inv6NxnJ13+/+Inv and NxnJ13/+6NxnJ13/+mice. The
day that a vaginal plug was observed was designated E0.5.
Embryos were dissected at E15.5 and E18.5, visualized by light
microscopy with a Leica microscope (Diagnostic Instruments), and
photographed using a SPOT digital camera. Mice at E18.5 were
weighed with a laboratory balance (Mettler Toledo) and Student’s
t-tests were carried out to determine significance.
Skeletal preparations
Whole-mount skeletal/cartilage preparations were carried out
with solutions containing alcian blue, which stains cartilage, and
alizarin red, which stains mineralized bone. The skin and the
internal organs were removed from E18.5 and P0 mice, fixed
overnight in 95% ethanol, stained overnight with an alcian blue
solution (0.015% alcian blue 8GX from Sigma, 20% acetic acid,
80% ethanol), transferred to 95% ethanol for at least three hours,
transferred to 2% KOH for at least 24 hours, stained overnight
with an alizarin red solution (0.005% alizarin sodium sulfate from
Sigma, 1% KOH), cleared for at least two days with 1% KOH/
20% glycerol, and stored in a 1:1 mix of glycerol and 95% ethanol.
The entire procedure was carried out at room temperature. Adobe
Photoshop 6.0 was used to measure the lengths of mandibles and
femurs and Student’s t-tests were performed to determine if
significant differences in bone length occurred.
Calculations of mutation distribution and mutation rate
1) Poisson distribution of lesions:
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ne{p
n!
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Chi-square goodness of fit X2 = 3.99 5 degrees of freedom
2) Mutation rate:
17,414 STSs were designed of which 15,673 were
successfully amplified.
Average 500 bp per read = 7.8 Mb linear transcribed
sequence per mutant line.
Average 80% successful reads = 6.27 Mb per line.
64*/6.276106640* mutants = 2.661027
*The lesion in Hes7 is not included here because the
l11Jus48 line was not sequenced for the full linear
transcribed sequence.
Supporting Information
Figure S1 Sequencing chromatograms of confirmed ENU-
induced mutations. All chromatograms are shown with control
strain sequence on top and heterozygous or homozygous mutant
sequence on bottom. { Forward strand sequence shown in
chromatogram.
Found at: doi:10.1371/journal.pgen.1000759.s001 (8.15 MB
DOC)
Figure S2 NxnJ13 mutants. (A–D) Comparison of femur length
with mandible length in NxnJ13/J13 mutants. At the top are the
mandibles showing a seven percent difference in length (also
shown in Figure 4). At the bottom are the femurs showing no
significant difference in length (p = 0.29). Error bars show the 95%
confidence interval around the mean (n= 10 per genotype,
mandibles and femurs). Controls were all heterozygous animals.
(E) Intestines in control and mutant animals at P0. Homozygous
mutants have air in the intestines, indicating a suckling defect. (F)
Genotypes of offspring from NxnJ13+/+Inv6NxnJ13+/+Inv mat-
ings. (A) Homozygous Inv(11)8Brd disrupts Wnt3, and no mice
were obtained with this genotype, therefore the expected ratio is
2:1. (B) Fisher exact tests with two-tailed p values.
Found at: doi:10.1371/journal.pgen.1000759.s002 (0.14 MB TIF)
Table S1 Sequence contigs on mouse Chromosome 11. The
cumulative gap size is approximately 100 kb and centromere
(3 Mb allocated in Accessioned Golden Pathy) (AGP). Note:
Telmeric sequence reached. * Optical Map is a technique for
generating a high resolution map of the structure of a chromosome
or genome.
Found at: doi:10.1371/journal.pgen.1000759.s003 (0.02 MB
DOC)
Table S2 Gene content differences between mouse and human.
Found at: doi:10.1371/journal.pgen.1000759.s004 (0.03 MB
DOC)
Table S3 Structural characteristics of annotated genes structures
from mouse Chromosome 11. 1 Of these, 450 were processed
transcripts that were not likely to encode a protein.
Found at: doi:10.1371/journal.pgen.1000759.s005 (0.04 MB
DOC)
Table S4 Variants found by resequencing exons and their
flanking 125 bp in the Trp53-Wnt3 interval. Lesions found only
once in a single line are shown. Each lesion was confirmed by re-
sequencing 2–4 DNAs from additional mutant individuals from
each line. The B6/129 SNPs are likely to be new SNPs that arose
in our substrain, or may not have been identified. No mutations
were found or confirmed in 8 lines (crf05, inf4, gro40, l11Jus38,
l11Jus45, nur01, nur05, and skc1). Hom: Indicates that DNA from a
homozygous mutant was used for re-sequencing. Het: Indicates that
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DNA from a heterozygous mutant was used for re-sequencing.
F: Denotes forward gene, forward strand sequence provided
(coding sequence). R: Denotes reverse gene, reverse complement
of forward strand sequence provided (coding sequence). 1 Twelve
lesions did not confirm in any animals giving an error rate
for re-sequencing of 15% (12/80). 2 Mutation was discovered
independently of chr 11 resequencing effort. 3 Unable to suc-
cessfully PCR and amplify and sequence the genomic region
flanking this mutation so this mutation was not confirmed. 4 Kile,
B.T. et. al. Nature 2003 [5]. 5 Traka, M. et. al. J. Neurosci.
2008 [19].
Found at: doi:10.1371/journal.pgen.1000759.s006 (0.22 MB
DOC)
Table S5 Allelic series found. Exon number, intron numbers,
and the size of the genomic loci are taken from Ensembl version
34. 1 Four additional lesions found in Aipl1, Atp6v0a1,Plxdc1, and
Socs7. 2 One additional lesion found in Tmigd1. 3 Two additional
lesions found in Plekhm1, RP23-263M10.5. 4 One additional lesion
found in Olfr394. 5 Three additional lesions found in Centb1, Gip,
Mpdu1.
Found at: doi:10.1371/journal.pgen.1000759.s007 (0.05 MB
DOC)
Table S6 Known genes associated with mutant alleles that lie in
the Trp53-Wnt3 interval.
Found at: doi:10.1371/journal.pgen.1000759.s008 (1.05 MB
DOC)
Table S7 Primers used to confirm Chromosome 11 ENU-
induced mutations.
Found at: doi:10.1371/journal.pgen.1000759.s009 (0.12 MB
DOC)
Table S8 Microsatellite markers and SNPs used in mapping
l11Jus13 (NxnJ13). PCR conditions are available upon request. F
denotes forward primer, R denotes reverse primer.
Found at: doi:10.1371/journal.pgen.1000759.s010 (0.06 MB
DOC)
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